428 related articles for article (PubMed ID: 17208336)
1. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
[TBL] [Abstract][Full Text] [Related]
2. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.
Schmand B; Huizenga HM; van Gool WA
Psychol Med; 2010 Jan; 40(1):135-45. PubMed ID: 19863841
[TBL] [Abstract][Full Text] [Related]
5. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
7. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
8. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.
Bouwman FH; Schoonenboom SN; van der Flier WM; van Elk EJ; Kok A; Barkhof F; Blankenstein MA; Scheltens P
Neurobiol Aging; 2007 Jul; 28(7):1070-4. PubMed ID: 16782233
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
[TBL] [Abstract][Full Text] [Related]
10. CSF biomarker levels in early and late onset Alzheimer's disease.
Bouwman FH; Schoonenboom NS; Verwey NA; van Elk EJ; Kok A; Blankenstein MA; Scheltens P; van der Flier WM
Neurobiol Aging; 2009 Dec; 30(12):1895-901. PubMed ID: 18403055
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration.
Kapaki E; Paraskevas GP; Papageorgiou SG; Bonakis A; Kalfakis N; Zalonis I; Vassilopoulos D
Alzheimer Dis Assoc Disord; 2008; 22(1):47-53. PubMed ID: 18317246
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
Formichi P; Battisti C; Radi E; Federico A
J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
16. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
[TBL] [Abstract][Full Text] [Related]
17. Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects.
Verwey NA; Kester MI; van der Flier WM; Veerhuis R; Berkhof H; Twaalfhoven H; Blankenstein MA; Scheltens And P; Pijnenburg YA
J Alzheimers Dis; 2010; 20(2):445-52. PubMed ID: 20164558
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
Galasko D
J Neural Transm Suppl; 1998; 53():209-21. PubMed ID: 9700659
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Rusinek H; Li J; Tsui W; Saint Louis LA; Clark CM; Tarshish C; Li Y; Lair L; Javier E; Rich K; Lesbre P; Mosconi L; Reisberg B; Sadowski M; DeBernadis JF; Kerkman DJ; Hampel H; Wahlund LO; Davies P
Neurobiol Aging; 2006 Mar; 27(3):394-401. PubMed ID: 16125823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
